Published in Radiat Oncol on May 11, 2010
The autophagy-inducing drug carbamazepine is a radiation protector and mitigator. Int J Radiat Biol (2011) 0.98
Internalization of C60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex. Biomaterials (2012) 0.85
Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation. Transl Cancer Res (2013) 0.82
Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion. Zebrafish (2014) 0.75
Radioprotective Effect of Beta D-Glucan and Vitamin E on Gamma Irradiated Mouse. J Clin Diagn Res (2017) 0.75
The chemistry and biology of nitroxide compounds. Free Radic Biol Med (2007) 2.76
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol (2008) 2.32
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys (1991) 1.53
Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem (2005) 1.43
Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res (1992) 1.34
Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol (2009) 1.29
Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord (2001) 1.25
The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials (2008) 1.19
Radiation countermeasure agents: an update. Expert Opin Ther Pat (2010) 1.11
In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol (2008) 1.05
Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle (2008) 1.03
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res (2006) 1.02
Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res (2007) 1.01
Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha. Radiat Res (2007) 1.00
Antioxidant single-walled carbon nanotubes. J Am Chem Soc (2009) 0.99
Identification of nitroxide radioprotectors. Radiat Res (1992) 0.97
Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat Res (2007) 0.96
Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2. Radiat Res (1976) 0.95
Visualizing the uptake of C60 to the cytoplasm and nucleus of human monocyte-derived macrophage cells using energy-filtered transmission electron microscopy and electron tomography. Environ Sci Technol (2007) 0.94
SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine (2008) 0.93
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice. Basic Clin Pharmacol Toxicol (2008) 0.90
Fullerene derivatives protect endothelial cells against NO-induced damage. Nanotechnology (2009) 0.86
Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat Res (1970) 0.85
In vitro evaluation of some latent radioprotective compounds. Int J Radiat Biol Relat Stud Phys Chem Med (1976) 0.85
Potential radioprotective agents. 1. Homologs of melatonin. J Pharm Sci (1994) 0.85
Induction of marrow hypoxia by radioprotective agents. Radiat Res (1989) 0.83
Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats. Colloids Surf B Biointerfaces (2007) 0.81
Fullerenes as a new class of radioprotectors. Int J Radiat Biol (2001) 0.80
The polyhydroxylated fullerene derivative C60(OH)24 protects mice from ionizing-radiation-induced immune and mitochondrial dysfunction. Toxicol Appl Pharmacol (2009) 0.80
On the mechanism of action of fullerene derivatives in superoxide dismutation. Chemistry (2010) 0.79
N-acyl dehydroalanines protect from radiation toxicity and inhibit radiation carcinogenesis in mice. Carcinogenesis (1989) 0.78
Antioxidant action of sugar-pendant C60 fullerenes. Bioorg Med Chem Lett (2009) 0.77
Modulating the Radiation Response. Oncologist (1996) 0.77
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
The chemistry and biology of nitroxide compounds. Free Radic Biol Med (2007) 2.76
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell (2004) 2.73
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proc Natl Acad Sci U S A (2002) 2.62
Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res (2002) 2.56
The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells (2006) 2.50
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol (2002) 2.23
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell (2012) 1.99
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res (2007) 1.91
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys (2010) 1.84
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res (2013) 1.81
Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest (2008) 1.71
Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist (2010) 1.71
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res (2009) 1.69
Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res (2003) 1.69
Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med (2010) 1.65
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am J Pathol (2003) 1.64
Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J Natl Cancer Inst (2013) 1.64
Absolute oxygen tension (pO(2)) in murine fatty and muscle tissue as determined by EPR. Magn Reson Med (2005) 1.63
Single-point (constant-time) imaging in radiofrequency Fourier transform electron paramagnetic resonance. Magn Reson Med (2002) 1.56
Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination. Magn Reson Med (2006) 1.50
Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet (2004) 1.50
Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res (2010) 1.49
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res (2010) 1.48
Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem (2004) 1.46
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.44
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther (2007) 1.42
Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res (2006) 1.39
Noninvasive in vivo oximetric imaging by radiofrequency FT EPR. Magn Reson Med (2002) 1.39
Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci U S A (2012) 1.38
Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol (2004) 1.38
High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res (2006) 1.38
Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR. Magn Reson Med (2007) 1.37
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res (2003) 1.35
Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res (2007) 1.34
Imaging cycling tumor hypoxia. Cancer Res (2010) 1.32
Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res (2002) 1.32
A method of high frequency virus-induced gene silencing in chili pepper (Capsicum annuum L. cv. Bukang). Mol Cells (2004) 1.32
CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood (2004) 1.28
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res (2005) 1.27
Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem (2006) 1.22
Pharmacokinetics of a triarylmethyl-type paramagnetic spin probe used in EPR oximetry. Magn Reson Med (2004) 1.22
Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res (2008) 1.22
MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn Reson Med (2006) 1.21
Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res (2011) 1.19
Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci U S A (2009) 1.18
A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med (2003) 1.18
Prevention of irradiation-induced salivary hypofunction by microvessel protection in mouse salivary glands. Mol Ther (2007) 1.18
Evaluation and comparison of pulsed and continuous wave radiofrequency electron paramagnetic resonance techniques for in vivo detection and imaging of free radicals. J Magn Reson (2002) 1.13
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer (2008) 1.12
The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res (2004) 1.10
Pulsed EPR imaging of nitroxides in mice. J Magn Reson (2008) 1.09
Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One (2011) 1.08
Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice. Proc Natl Acad Sci U S A (2008) 1.07
Prevention of radiation-induced oral mucositis after adenoviral vector-mediated transfer of the keratinocyte growth factor cDNA to mouse submandibular glands. Clin Cancer Res (2009) 1.07
Prevention of radiation-induced salivary hypofunction following hKGF gene delivery to murine submandibular glands. Clin Cancer Res (2011) 1.07
Brain redox imaging using blood-brain barrier-permeable nitroxide MRI contrast agent. J Cereb Blood Flow Metab (2008) 1.06
Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res (2004) 1.04
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging. J Pharm Pharmacol (2008) 1.02
Nitric oxide and cancer: an introduction. Free Radic Biol Med (2003) 1.02
n-Alkyl glucopyranosides completely inhibit ultrasound-induced cytolysis. Free Radic Biol Med (2005) 1.02
Tumor hypoxia: chicken, egg, or a piece of the farm? J Clin Oncol (2002) 1.02
Spatially resolved biologic information from in vivo EPRI, OMRI, and MRI. Antioxid Redox Signal (2007) 1.01
Evaluation of radiation-induced oral mucositis by optical coherence tomography. Clin Cancer Res (2005) 1.01
Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid Redox Signal (2004) 1.00
Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res (2008) 1.00
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol (2010) 1.00
Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor. Hum Mol Genet (2005) 1.00
In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing. Magn Reson Med (2002) 0.99
Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim Biophys Acta (2005) 0.99
Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med (2010) 0.99
Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. J Am Chem Soc (2002) 0.99